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Abstract Liposomes are widely used, from biosensing to
drug delivery. Their coating with polymers for stability and
functionalization purposes further broadens their set of rel-
evant properties. Poly(dopamine) (PDA), a eumelanin-like
material deposited via the ‘‘self’’-oxidative polymerization
of dopamine at mildly basic pH, has attracted considerable
interest in the past few years due to its simplicity, flexibility
yet fascinating properties. Herein, we characterize the
coating of different types of liposomes with PDA depending
on the presence of oleoyldopamine in the lipid bilayer and
the dopamine hydrochloride concentration. Further, the
interaction of these coated liposomes in comparison to their
uncoated counterparts with myoblast cells is assessed. Their
uptake/association efficiency with these cells is determined.
Further, their dose-dependent cytotoxicity with and without
entrapped hydrophobic cargo (thiocoraline) is characterized.
Taken together, the reported results demonstrate the poten-
tial of PDA coated liposomes as a tool in biomedical
applications.
1 Introduction
Liposomes are among the most prominent objects
employed in bionanotechnology. In addition to their
application as drug delivery vehicles [1, 2], they are also
employed in biosensing as labels [3] or as carriers for
membrane proteins [4]. Further, they have recently been
considered as sub-compartments in polymer capsules
towards therapeutic cell mimicry [5–7] or as potential drug
deposits embedded in polymer films on surfaces [8, 9].
The combination of polymers with liposomes is interest-
ing in many aspects; beneficial properties from both mate-
rials are preserved, while shortcomings can be overcome.
Coating liposomes with poly(ethylene glycol) (PEG) using
PEGylated lipids is the typical and to date the most suc-
cessful way to increase the circulation time [10, 11] when
liposomes are used in drug delivery. Alternative coatings
such as mucoadhesive polymers, e.g. chitosan, have been
considered to improve the mucoadhesive properties [12] or
modifications based on the sequential deposition of inter-
acting polymers onto liposomes [13]. Although improved
properties in terms of stability and cargo retention have been
observed in the latter case, the separation of the free polymer
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during the assembly process is a limiting step. Alternatively,
Ali et al. [14] proposed a reversible addition-fragmentation
chain transfer (RAFT)-based approach by initially deposit-
ing a short polyelectrolyte onto liposomes. The polymer shell
thickness was increased by taking advantage of the ‘‘living’’
RAFT moieties which allowed for the further polymer chain
extension in the presence of monomers. Once initiated, the
polymer shell is ‘‘self’’-deposited, making this approach
potentially widely applicable. On the other hand, the success
of the coating relies on the synthesis and deposition of the
first polyelectrolyte.
Polydopamine (PDA) [15], a dopamine-derived syn-
thetic polymer, has recently attracted considerable interest
as a flexible coating toward biomedical applications [16].
PDA is deposited via a ‘‘self’’-oxidative process at slightly
basic pH on virtually any substrate, independent of material
and shape. Many fundamental aspects of PDA have yet to
be discovered and characterized, but its photoprotective or
electrical properties and options for straight-forward post-
functionalization using amines or thiols are making this
material highly attractive. Thus, PDA coatings have been
considered in a variety of different applications, ranging
from controlling cell/surface interactions e.g. rendering
hydrophobic surface cell adhesive [17] to building blocks
in biosensing platforms e.g. as matrix polymer for molec-
ular imprinting [18], and for life cell encapsulation [19].
PDA capsules have been considered using particles [20–
23] or oil emulsion droplets [24] as templates. Although
cargo loading in PDA capsules has been shown, no impact
on the cell viability due to the presence of the cargo has
been reported and only the absence of inherent cytotoxicity
has been demonstrated. Also, the requirement to remove
the core potentially limits these approaches. We recently
considered PDA coatings for surface-mediated drug
delivery by embedding liposomes into the polymer film
and demonstrated the uptake of fluorescent lipids from the
surface [8]. In this context, we employed X-ray photo
spectroscopy to ensure the PDA formation on the liposome
coated surfaces, but no further detailed characterization of
PDA/liposome interactions has yet been performed.
Herein, we report the coating of liposomes with PDA
(Fig. 1) and assess the interaction of myoblast cells with these
assemblies as a first step toward their application in drug
delivery. In particular we (i) synthesize oleoyldopamine (OD),
Fig. 1 Schematic illustration of
the PDA coating of liposomes
containing OD in the lipid
bilayer. A dopamine solution is
mixed with a liposome solution
(i) and left to react (ii). The
sample is then dialyzed yielding
a solution of PDA coated
liposomes (iii)
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(ii) monitor the PDA growth on positively, zwitterionic and
negatively charged liposomes with and without OD in their
lipid membrane, and (iii) characterize the uptake efficiency of
exemplified PDA coated and uncoated liposomes by myoblast
cells as well as (iv) the cell cytotoxicity of empty and thio-
coraline (TC) loaded PDA coated and uncoated assemblies.
This report is the first detailed characterization of lipo-
some/PDA interaction toward the potential application as
drug delivery vehicles.
2 Experimental
2.1 Materials
Sodium chloride (NaCl), tris(hydroxymethyl)aminomethane
(TRIS) buffer, dimethyl sulfoxide (DMSO), dopamine
hydrochloride (dopamine), phosphate buffered saline (PBS),
and chloroform were purchased from Sigma-Aldrich.
Zwitterionic lipids 1-palmitoyl-2-oleoyl-sn-glycero-3-phos-
phocholine (POPC, 25 mg/mL), negatively charged lipids
1-palmitoyl-2-oleyl-sn-glycero-3-phospho-L-serine (sodium
salt) (POPS, 25 mg/mL), positively charged lipids 1-palmi-
toyl-2-oleoyl-sn-glycero-3-ethylphosphocholine (POEPC,
25 mg/mL), and fluorescent lipids 1-oleoyl-2-[6-[(7-nitro-
2-1,3-benzoxadiazol-4-yl)amino]hexanoyl]-sn-glycero-
3-phosphocholine (NBD-PC) dissolved in chloroform were
obtained from Avanti Polar Lipids, USA. Thiocoraline (TC)
was isolated and purified by PharmaMar, S.A. (Colmenar
Viejo, Madrid, Spain).
Two types of buffers were used throughout all of the
liposome coating experiments: TRIS1 buffer consisting of
10 mM TRIS (pH 8.5) and TRIS2 buffer consisting of
10 mM TRIS and 150 mM NaCl (pH 7.4). All water used
in these experiments was tapped from the Millipore water
system (Milli-Q gradient A 10 system, resistance 18 MX
cm, TOC \ 4 ppb, Millipore Corporation, USA).
2.2 Synthesis of Oleoyldopamine
N-Oleoyl dopamine, a commercially available compound
with biomedical research interest [25–27] was synthesized
via the amidation of oleoyl chloride.
Oleoyl chloride was synthesized according to standard
acid chloride synthesis via oxalyl chloride obtaining a
similar yield as published [28].
Dopamine hydrochloride (1.89 g, 9.97 mmol) was dis-
solved in dry dimethylformamide (DMF, 25 mL) at room
temperature (RT), under argon in a two neck round bottom
flask (100 mL). Triethylamine (TEA, 1.51 g, 14.9 mmol)
was added dropwise under stirring and then cooled to
-20C in an ethanol/dry ice bath. Oleoyl acid chloride
(1.5 g, 4.98 mmol) was dissolved in dry dichloromethane
(DCM) and added dropwise over 1 h to the reaction at
-20C. After addition, the heterogeneous mixture was
allowed to come to 0C for 40 min, and then brought to RT
and left over night.
The reaction mixture was diluted with 75 mL DCM and
washed 29 with 0.5 M potassium bisulfate (50 mL), water
(25 mL), brine (50 mL) and filtered through silica. The
material was dried under vacuum to solidify to an off-white
waxy solid. This was dissolved in methanol and precipi-
tated with the addition of water (29) to give white crystals,
1.58 g (88.9% yield), HPLC purity [99%.
1H NMR (CDCl3, 400 MHz) d 7.75, s, 1H, OH; 6.81, d,
J 8.0 Hz, 1H, CH (Ar); 6.75, d, J 2.0 Hz, 1H, CH (Ar);
6.56, dd, J 8.0, 1.9 Hz, 1H, CH (Ar); 6.07, s, 1H, OH; 5.63,
t, J 5.6 Hz, 1H, NH; 5.34, m, 2H, =CH; 3.48, m, 2H,
CH2N; 2.69, t, J 7.1 Hz, 2H, CH2Ar; 2.15, m, 2H, CH2CO;
1.99, m, 4H, CH2CH=; 1.58, m, 2H, CH2CH2CO; 1.26, m,
20H, CH2; 0.88, t, J 6.8 Hz, 3H, CH3.
2.3 Liposome Formation
Unilamellar liposomes were prepared by evaporation of the
chloroform of the lipid solutions under vacuum for 1 h.
Zwitterionic liposomes consisted of 2.5 mg POPC lipids
with 0 wt% OD (LOD_0
zw ), 0.5 wt% OD (LOD_0.5
zw ), or
2.5 wt% OD (LOD_2.5
zw ). Negatively charged liposomes were
made from 0.5 mg POPS and 2 mg POPC lipids with
0 wt% OD (LOD_0
- ), 0.5 wt% OD (LOD_0.5
- ), or 2.5 wt% OD
(LOD_2.5
- ). Positively charged liposomes consisted of
0.5 mg POEPC and 2 mg POPC lipids with 0 wt% OD
(LOD_0
? ), 0.5 wt% OD (LOD_0.5
? ), or 2.5 wt% OD (LOD_2.5
? ).
For fluorescently labelled liposomes (NBDL), 0.5 wt% of
NBD-PC was added to the lipid solution. Thiocoraline
(TC) loaded liposomes (TCL) were assembled by adding
100 lL (0.1 mg/mL) TC in chloroform to the lipid mixture
prior to drying. This TC concentration was chosen to
ensure the highest amount of incorporated cargo into the
lipid membrane of the liposomes based on our previous
reports [29, 30]. Thus, increasing TC concentration above
0.1 mg/mL does not results in an increase in the amount of
liposome-loaded TC. The dried lipid film was rehydrated
with 1 mL TRIS1 buffer and the solution was extruded
through 100 nm filters (11 times).
2.4 PDA Coating of Liposomes
The nine types of liposomes were coated with PDA
according to the following protocol. 10 mg/mL dopamine
stock solution in TRIS1 buffer was prepared and used as is
or diluted to two different dopamine concentrations (2 and
5 mg/mL) using TRIS1 buffer. Typically, 125 lL of lipo-
some solution was mixed with 125 lL dopamine solution
leading to dopamine concentrations of D1 = 1 mg/mL,
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D2.5 = 2.5 mg/mL and D5 = 5 mg/mL during coating.
Three control samples of 125 lL dopamine (2, 5 and
10 mg/mL) mixed with 125 lL TRIS1 buffer were run in
parallel. The samples were permanently shaken during the
coating process. The size and polydispersity (PD) of the
samples was determined at different time points by diluting
30–50 lL sample solution in 700 lL TRIS1 prior to mea-
suring in a dynamic light scattering (DLS) instrument (Zeta-
sizer nano, Malvern Instruments) using a material refractive
index of 1.590 and a dispersant (water at 25C) refractive
index of 1.330. Within this paper, samples with a PD [ 0.4
were considered aggregated and were discarded. As the final
step, the PDA coating process was stopped and the free
dopamine and small PDA aggregates in solution were
removed by diluting the sample 1:1 v/v with TRIS2 buffer
followed by dialysis against TRIS2 buffer overnight. This step
also adjusted the buffer solution to physiological conditions.
The long-term stability of LOD_0
? and LOD_0
? D2.5 was
assessed by storing them in either TRIS2 buffer or TRIS2
buffer supplemented with 2 mg/mL BSA at T = 4C, at
room temperature or at T = 37C. Their size and PD was
regularly measured by DLS over max 3 weeks.
For the subsequent experiments, LOD_0
? (supplemented with
NBD-PC or TC if required) using 1 or 2.5 mg/mL dopamine
(LOD_0
? D1 or LOD_0
? D2.5) and a polymerization time of 75 min
was chosen. As a control, samples of LOD_0
? without dopamine
but with the same dilution steps were also prepared.
2.5 Cryo-Transmission Electron Microscopy
(cryo-TEM)
Samples were prepared for cryo-TEM by adsorbing 4 ll of
the liposome suspension onto Quantifoil R3.5/1 holey
carbon film mounted on 300 mesh copper grids (Quantifoil
Micro Tools GmbH, Jena, Germany). Prior to adsorption,
the grid was rendered hydrophilic by glow discharge in a
reduced atmosphere of air for 10 s. The specimen was
applied and after 1 min incubation on the surface, the grid
was blotted and quick-frozen in liquid ethane using a
Vitrobot automated plunging device (FEI Company,
Eindhoven, The Netherlands).
The frozen grids were transferred to liquid nitrogen before
loading into a Gatan 626 cryo-holder (Gatan, Pleasanton, CA,
USA). The cryo-holder was then inserted into the stage of a
Philips CM200 FEG TEM (FEI company) operated at
200 kV. Imaging was performed at cryogenic temperatures
(approx. -170C) in low-dose, bright-field mode. Electron
micrographs were recorded digitally on a TVIPS 4 k 9 4 k
CMOS Camera (TVIPS GmbH, Gauting Germany) at given
defocus values of -2.5 lm.
2.6 Cell Experiments
The C2C12 mouse myoblast cell line was used for all the
experiments. The cells were cultured as monolayers in
75 cm2 culture flasks in medium (Dulbecco’s modified
Eagle’s Medium with Glutamax (DMEM) supplemented
with 10% fetal bovine serum, 50 U/mL penicillin, 50 lg/mL
streptomycin and 1 mM sodium pyruvate, all from Invitro-
gen) at 37C and 5% CO2. The cells were seeded into 96-well
plates at a density of 7,500 cells/well in 200 lL medium and
allowed to attach for 20 h at 37C and 5% CO2 prior to the
uptake and cell viability experiments.
2.6.1 Uptake Experiments
8 or 32 lL of NBDLOD_0
? or NBDLOD_0
? D2.5 solution was
added per well and the cells were exposed to this liposome-
containing media for different time points (3, 6 or 24 h).
Then, the cells were washed 29 in 300 lL PBS, trypsini-
zed and re-suspended in 200 lL PBS for analysis by flow
cytometry. A C6 Flow Cytometer (Accuri Cytometers Inc)
using an excitation wavelength of k = 488 nm was
employed to measure the fluorescence intensity of the cells
upon their association with these assemblies. At least 3,000
cells were analyzed. The experiments were performed in
triplicates and three independent repeats.
2.6.2 Cell Viability
The amount of encapsulated TC was quantified by fluo-
rescence spectrophotometry. The different samples were
excited at a wavelength of 365 nm and the fluorescence
intensity was recorded at an emission wavelength of
547 nm. The concentration of TC was determined by
correlation with a calibration curve (Figure S1, Supporting
Information). The experiments were carried out using a multi
plate reader (PerkinElmer). The averaged encapsulated
TC in the TCLOD_0
? stock solution was 7.5 ± 1.8 lg/mL.
We further assumed that the PDA coating does not affect the
TC retention. TCLOD_0
? or TCLOD_0
? D1 solutions with different
concentrations (between 0 and 1.2 lg/mL) of TC were added
per well and incubated with the cells for 24 h. The cell via-
bility was assessed using the Cell Counting Kit-8 (Dojindo)
by adding 20 lL assay solution per well and an incubation
time of 2 h prior to the absorbance read out using a multi
plate reader (PerkinElmer). The results were background
corrected by subtracting the absorbance reading for
media only and normalized to untreated cells. The experi-
ments were performed in triplicates and three independent
repeats.
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3 Results and Discussion
3.1 PDA Coating of Liposomes
With the aim to characterize the effect of the lipid com-
position and the presence of OD in the lipid membrane on
the PDA growth rate, zwitterionic, negatively, and posi-
tively charged liposomes with different amounts of incor-
porated OD were exposed to dopamine solutions with
different concentration. OD was embedded within the
membrane with the goal to facilitate the PDA deposition i.e.
to serve as anchor since it will copolymerize with the
dopamine/PDA. The change in liposome diameter and PD
over time was monitored using DLS (Fig. 1i, ii). We would
like to note that the quantitative change in diameter could be
misleading due to the deposited PDA around the liposomes.
This black coating is expected to absorb the laser light and
thus could affect the outcome of the measurement. How-
ever, qualitatively it is nonetheless possible to compare the
PDA growth rates between the different samples. Figure 2
summarizes the result for the zwitterionic liposomes. In
general, both the presence of OD and the different con-
centrations of dopamine affected the PDA growth rate.
Increasing amounts of OD led to faster PDA growth rates
for the same dopamine concentration. On the other hand,
increasing concentration of dopamine did not affect the
PDA growth rate, but sample aggregation was observed
after shorter times. After a max of 120 min, all the tested
samples had a PD [ 0.4 and were considered aggregated
[marked by an asterisk (*) in Fig. 2]. While the presence of
OD could be an advantage in a different context e.g. when
the liposomes are adsorbed to the surface prior to the PDA
coating, here, for the PDA coating of zwitterionic liposomes
in solution, a too high amount of OD is not beneficial.
On the other hand, the presence of OD in negatively
charged liposomes was neither affecting the PDA growth
rate nor the aggregation behavior of the samples (Fig. 3).
However, in this case increasing amounts of dopamine
yielded faster growth of the liposome’s diameter. Only the
highest dopamine concentration tested caused aggregation
of the samples after a max of 120 min. All the other
combinations preserved a PD \ 0.4.
The coating of the third type of tested liposomes, the
positively charged ones, was neither affected by OD nor by
increasing amounts of dopamine, but exhibited a slow but
stable PDA growth during the max monitored time of
800 min (Fig. 4). These observations suggest that the
electrostatic interaction of the dopamine with the lipo-
somes is dominating over the presence of OD. Further,
DLS measures the hydrodynamic radius and therefore, the
properties i.e. stiffness of the deposited PDA film, could
vary depending on the type of liposomes used as template.
Fig. 2 Time-course of the normalized increase in diameter for the
PDA assembly on zwitterionic liposomes with three different amounts
of OD [(i) 0, (ii) 0.5 and (iii) 2.5 wt%] using three different
concentrations of dopamine (1, 2.5 and 5 mg/mL). All the samples
had a PD [ 0.4 after 120 min as indicated by asterisks
Biointerphases (2012) 7:8 Page 5 of 9
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Fig. 3 Time-course of the normalized increase in diameter for the
PDA assembly on negatively charged liposomes with three different
amounts of OD [(i) 0, (ii) 0.5 and (iii) 2.5 wt%] using three different
concentrations of dopamine (1, 2.5 and 5 mg/mL). The asterisks
indicates samples with a PD [ 0.4
Fig. 4 Time-course of the normalized increase in diameter for the
PDA assembly on positively charged liposomes with three different
amounts of OD [(i) 0, (ii) 0.5 and (iii) 2.5 wt%] using three different
concentrations of dopamine (1, 2.5 and 5 mg/mL)
Page 6 of 9 Biointerphases (2012) 7:8
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However, the qualitative comparison between the different
samples is still valid. A detailed investigation of this aspect
is beyond the scope of this initial paper and will be part of a
subsequent publication. Although positively charged lipo-
somes had the slowest PDA growth rate, the absence of
aggregation makes them the most suitable candidates for
the purpose outlined in this paper.
Interestingly, dopamine solutions containing no lipo-
somes started to show aggregated PDA after 15–30 min
with sizes of 200–400 nm (PD * 0.3) which increased in
size such that they flocculated out of solution with several
micron sized aggregates (PD = 1) after 75 min (Fig. 5a,
left). On the other hand, when the liposomes e.g.
LOD_0
? were present in the dopamine solution of the same
concentration, the solutions turned a homogenous dark
brown (Fig. 5a, right). In general, this has been observed
independent of the type of liposomes used, but the effect
was more pronounced for the charged liposomes without
OD. While we do not fully understand the reasons, we
speculate that the liposomes were a preferred deposition
site over the PDA aggregates in solution themselves. This
fact allows for the purification of the coated liposomes by
dialysis only, without the need for additional steps such as
centrifugation.
While we are not aiming at assembling PDA capsules, i.e.
removal of the liposomes, but to equip the liposomes with a
stabilizing adhesive layer, LOD_0
? with 1 or 2.5 mg/mL
dopamine (LOD_
? D1 and LOD_
? D2.5) with a polymerization
time of 75 min was chosen for all the subsequent experi-
ments. The subsequent purification step via dialysis against
TRIS2 caused the PDA coating to keep growing and yielded
stable, PDA coated liposomes as shown in a representative
cryo-TEM image of LOD_0
? D1 in Fig. 5b. Cryo-TEM images
of LOD_0
? D2.5 looked very similar (Results not shown). It
demonstrates that the liposomes remained intact without
distortion or visible damage to the membrane due to the PDA
coating. However, it also shows that the diameter assessed by
DLS was overestimated, likely due to the effect of the light-
absorbing coating on the liposomes on the DLS measure-
ments. Further, no large PDA particles (\100 nm) were
observed confirming that dialysis as a purification step is
sufficient. The PDA coated liposomes were found to be
stable for at least 2 weeks at 4C, room temperature, and
37C in TRIS2 buffer with and without BSA (results not
shown).
3.2 Interaction of PDA Coated Liposomes
with Myoblast Cells
Since we aim to use the coated liposomes as drug delivery
vehicles or as subunits in larger assemblies, we charac-
terized the uptake efficiency by myoblast of NBDLOD_0
? D2.5
in comparison to uncoated NBDLOD_0
? . All the diameters
mentioned were measured by DLS, and as pointed out
previously the dark coating was likely to affect the read
out, allowing only qualitative comparing between the dif-
ferent samples. In order to understand how the LOD_0
? D2.5
association with the myoblast cells evolves over time,
myoblast cells were incubated with two different concen-
trations of NBDLOD_0
? D2.5 or
NBDLOD_0
? for 3, 6 or 24 h
followed by the monitoring of the fluorescence intensity of
the cells by flow cytometry (Fig. 6). The uptake efficiency
showed that after 6 h 100 and 80% of the cells in the
population had liposomes associated with them for the
higher and lower tested concentration, respectively and
remained on a similar level for the tested 24 h (Fig. 6, left).
In parallel, the mean fluorescence of the cells, as a more
quantitative measure of the amount of liposomes associated
per cell, showed that the 49 higher concentration of
LOD_0
? D2.5 or LOD_0
? resulted in *49 higher fluorescence
intensity of the cells (Fig. 6, right). Further, although the
Fig. 5 a Photographs of solutions containing 2.5 mg/mL dopamine
in TRIS1 (left) or 2.5 mg/mL dopamine and LOD_0
? in TRIS1 (right)
after 75 min, showing a flocculated (left) and a homogenous (right)
dark brown solution, respectively. b Cryo-TEM image of LOD_0
? D1
showing structurally intact liposomes
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fluorescence intensity of the NBDLOD_0
? D2.5 and
NBDLOD_0
?
solutions were within ±10% as measured by fluorescence
spectrophotometry, the fluorescence intensity of the myo-
blasts was doubled when exposed to LOD_0
? D2.5 as com-
pared to LOD_0
? . This suggests that the PDA coating might
promote their uptake by/association with the cells. In
addition, for most cases, the fluorescence intensity of the
cells dropped between 6 and 24 h, suggesting that the cells
either processed the fluorescent lipids or divided, and by
doing so were reducing the fluorescence intensity per cell.
The only exception was the higher concentration of
NBDLOD_0
? , probably due to the high concentration of lip-
osomes present but slower uptake/association kinetics
especially compared to LOD_0
? D2.5, again possibly
explained by the different outmost layer, PDA versus
phospholipids, and this aspect is currently part of a more
detailed investigation.
Understanding if the coated liposomes have inherent
cytotoxic effects is of crucial importance when these
assemblies are considered for biomedical applications i.e.
as drug delivery vehicles. To this end, we exposed different
concentrations of LOD_0
? D2.5, LOD_0
? D1, or LOD_0
? to myo-
blasts for 24 h and assessed the cell viability. There was no
significant effect on the viability of the cells observed for
both tested coating thicknesses, confirming the insignifi-
cant cytotoxicity of the PDA coating (Fig. 7a). This result
is in good agreement with the previously reported negli-
gible cytotoxicity of PDA capsules to LIM1215 cells [20].
In a next step, we employed the small cytotoxic
hydrophobic depsipeptide thiocoraline (TC),[31] in order
to investigate in a feasibility study, if the PDA coating
affects the potential cargo delivery. First, the entrapped TC
did not affect the PDA coating of the liposomes, yielding
TCLOD_0
? D1 with an average diameter of 393 ± 45 nm and
a PD of 0.18 ± 0.02, similar to what was measured for
LOD_0
? D1. A comparable dose dependent viability of the
Fig. 6 Uptake efficiency (left) and mean fluorescence (right) of myoblast cells incubated with NBDLOD_0
? or NBDLOD_0
? D2.5 (8 and 32 lL per
well) for different time points as measured by flow cytometry
Fig. 7 a Normalized cell viability of myoblast cells measured after
24 h exposure to different concentrations of LOD_O
? , LOD_0
? D1 and
LOD_0
? D2.5. b Normalized cell viability depending on the TC
concentration in TCLOD_0
? and TCLOD_0
? D1
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cells was observed when TC was entrapped within the lipid
bilayer of the liposomes for TCLOD_0
? and TCLOD_0
? D1
(Fig. 7b), suggesting that the presence of PDA and the used
coating thickness did not significantly hinder the activity
and release of TC, a compound which acts by unwinding
negatively supercoiled double-stranded DNA and binding
to DNA by bisintercalation [32].
4 Summary and Conclusions
We report the coating of liposomes with PDA and assess
the interaction of these assemblies with myoblast cells. The
PDA growth rate depended on the charge of the used lip-
osomes, the dopamine concentration and the presence of
OD within the lipid bilayer. The coated liposomes were
found to be stable in physiological conditions for at least
2 weeks and associated with myoblast cells in a similar
amount as for the uncoated liposomes. Further, the PDA
coating did not affect the viability of these cells unless the
cytotoxic depsipeptide TC was entrapped within the lipid
bilayer. Taken together, this first report on coating lipo-
somes with PDA demonstrates their potential as drug
delivery vehicle.
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